Phoenix, Arizona – November 2025 –

Infinitum Health, Inc., a biotechnology company pioneering evidence-based natural therapeutics, is proud to announce the appointment of Dr. Glen McCracken, MD, MBA to its Board of Directors. Dr. McCracken brings over two decades of clinical, operational, and executive experience in healthcare innovation, telemedicine, and clinical research leadership.

“Dr. McCracken’s deep expertise across emergency medicine, telehealth, and clinical trials will be instrumental as Infinitum Health enters its next phase of growth,” said Kevin T. Engholdt, MS, MBA, Founder and CEO of Infinitum Health. “His strategic insight at the intersection of medicine and business aligns perfectly with our mission to develop natural, biotechnology-driven solutions that improve and extend human health.”

A Leader in Modern Medicine and Innovation

Dr. McCracken currently serves as Chief Medical Officer at Direct2Care, where he is advancing access to high-quality care through digital health technology. He is also Chairman of the Board at Narcan4Life, Board Advisor at Reelay®, and previously served as Chief Medical Officer at CCT Research, where he helped shape innovative clinical trial methodologies.

Earlier in his career, Dr. McCracken founded eVisit, served on the Board of Directors at VirTrial, and held leadership roles with Scottsdale Emergency Associates and MedPro Group. His combined medical and business acumen has made him a sought-after voice in both clinical and corporate healthcare circles.

Dr. McCracken holds a Doctor of Medicine from Creighton University and a Master of Business Administration from the University of Arizona, reflecting his commitment to bridging patient care, technology, and organizational strategy.

“Infinitum Health represents a powerful convergence of biotechnology and natural medicine,” said Dr. Glen McCracken. “I’m excited to join the Board and help guide the company’s efforts to bring scientifically validated, natural solutions to some of healthcare’s biggest challenges.”

Strategic Growth and Leadership

Dr. McCracken’s appointment marks another milestone in Infinitum Health’s expansion as a newly incorporated C-Corporation. With ongoing research programs, a growing intellectual property portfolio, and preparations for Phase III clinical trials in oncology, virology, and pain management, the addition of Dr. McCracken strengthens the company’s strategic and clinical leadership.

About Infinitum Health

Infinitum Health, Inc. is a biotechnology company dedicated to developing natural, evidence-based products that support health and longevity. Founded by Kevin T. Engholdt, MS, MBA, the company integrates biotechnology, data modeling, and clinical research to create innovations in oncology, virology, and immune health. Its product portfolio includes Infinimin®, Infiniderm®, ReLeaf™, Ancient Cleanse™, Dragon Roast™ Coffee, and Immortalis™ Spirits—each designed to bridge the gap between nature and science.

For more information, visit: www.infinitumhealth.com